Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
5 min read
Strontium ranelate: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
24 October 2023
This article summarized the latest R&D progress of strontium ranelate, the Mechanism of Action for strontium ranelate, and the drug target R&D trends for strontium ranelate.
Latest Hotspot
3 min read
Shanghai Huaota Biopharmaceutical's IL-36R monoclonal antibody, HB0034, has been granted Orphan Drug Designation by the FDA for the treatment of generalized pustular psoriasis
24 October 2023
Shanghai Huaota Biopharmaceutical's HB0034 anti-IL-36R monoclonal antibody injection was granted orphan drug designation by the U.S. FDA for the treatment of generalized pustular psoriasis (GPP).
Drug Insights
5 min read
Oxitriptan Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
24 October 2023
This article summarized the latest R&D progress of oxitriptan, the Mechanism of Action for oxitriptan, and the drug target R&D trends for oxitriptan.
Valuable Targets
5 min read
Analysis on the Research Progress of Neurokinin 1 Receptor Antagonist
24 October 2023
Neurokinin-1 (NK1) receptor antagonists are used for prevention of acute and delayed nausea and vomiting.
Drug Insights
4 min read
Unleashing the Power of pamiparib: A Comprehensive Review on R&D Breakthroughs
24 October 2023
This article summarized the latest R&D progress of pamiparib, the Mechanism of Action for pamiparib, and the drug target R&D trends for pamiparib.
Latest Hotspot
3 min read
Shanghai Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab, announces Phase 3 trial data for the treatment of small-cell lung cancer
24 October 2023
The 2023 ESMO congress selected Shanghai Junshi Biosciences' phase III trial, EXTENTORCH, on anti-PD-1 monoclonal antibody toripalimab for the LBA.
Drug Insights
4 min read
A Comprehensive Review of peginterferon beta-1a's R&D Innovations and Drug Target Mechanism
24 October 2023
This article summarized the latest R&D progress of peginterferon beta-1a, the Mechanism of Action for peginterferon beta-1a, and the drug target R&D trends for peginterferon beta-1a.
Valuable Targets
3 min read
Analysis on the Clinical Research Progress of AMPK Inhibitor
24 October 2023
AMP-activated protein kinase (AMPK) is a crucial enzyme that plays a central role in regulating energy balance within the human body.
Drug Insights
4 min read
Pharmaceutical Insights: pimavanserin tartrate's R&D Progress and its Mechanism of Action on Drug Target
24 October 2023
This article summarized the latest R&D progress of pimavanserin tartrate, the Mechanism of Action for pimavanserin tartrate, and the drug target R&D trends for pimavanserin tartrate.
Bio Sequence
5 min read
Biological Glossary | What is Artificial Sequence?
24 October 2023
An artificial sequence is a sequence that is not naturally occurring but created by human manipulation.
Drug Insights
5 min read
Exploring polatuzumab vedotin-piiq's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
24 October 2023
This article summarized the latest R&D progress of polatuzumab vedotin-piiq, the Mechanism of Action for polatuzumab vedotin-piiq, and the drug target R&D trends for polatuzumab vedotin-piiq.
Latest Hotspot
3 min read
CStone Pharmaceuticals releases Phase 3 GEMSTONE-303 clinical trial data of anti-PD-L1 monoclonal antibody sugemalimab, for the treatment of gastric cancer
24 October 2023
The GEMSTONE-303 Phase III trial of CStone Pharmaceuticals' sugemalimab was selected for an LBA report at the 2023 ESMO conference.